XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
M
M

Morphosys


خبر

Morphosys Announces Voluntary Delisting From The Nasdaq Global Market

BRIEF-Morphosys Announces Voluntary Delisting From The Nasdaq Global Market July 12 (Reuters) - MorphoSys AG MORG.DE : EQS-NEWS: MORPHOSYS ANNOUNCES VOLUNTARY DELISTING FROM THE NASDAQ GLOBAL MARKET MORPHOSYS AG - EXPECTS THAT LAST TRADING DAY ON NASDAQ WILL BE ON OR ABOUT AUGUST 2, 2024 Source text for Eikon: ID:nEQ1B29X1a Further company coverage
M

Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00

BRIEF-Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00 July 12 (Reuters) - MORPHOSYS AG MORG.DE : MERGER SQUEEZE-OUT CASH COMPENSATION DETERMINED AT EUR 68.00 ANNOUNCES THAT NOVARTIS BIDCO GERMANY AG SUBMITTED A SPECIFIED REQUEST (KONKRETISIERTES VERLANGEN) TO MORPHOSYS AG MANAGEMENT BOARD COURT-APPOINTED EXPERT AUDITOR H
M

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N

Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO

BRIEF-Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO June 7 (Reuters) - MORPHOSYS AG MORG.DE : EQS-ADHOC: AD HOC: ARKADIUS PICHOTA AND LUKAS GILGEN APPOINTED TO MANAGEMENT BOARD OF MORPHOSYS AG REPLACING THE CURRENT CEO AND CFO Source text for Eikon: ID:nEQQh9gja Further company coverage: MORG.DE (Gdansk Newsroom)
M

Novartis Meets All Tender Offer Conditions To Acquire Morphosys

BRIEF-Novartis Meets All Tender Offer Conditions To Acquire Morphosys May 16 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS MEETS ALL TENDER OFFER CONDITIONS TO ACQUIRE MORPHOSYS AG FOR EUR 68 PER SHARE IN CASH SETTLEMENT OF SHARES TENDERED DURING INITIAL ACCEPTANCE PERIOD IS EXPECTED TO OCCUR ON 23 MAY 2024 Source text for Eikon: ID:nGNEcc97X3 Further
M
N

Novartis to buy radiology drug specialist Mariana for $1 billion

UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion Adds details on technology in paragraphs 5 and 6 By Andrey Sychev and Ludwig Burger May 2 (Reuters) - Novartis NOVN.S agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday.
M
N

Incyte misses quarterly profit on weak sales of lead drug

Incyte misses quarterly profit on weak sales of lead drug April 30 (Reuters) - Incyte Corp INCY.O on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade.
I
M
N

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Impossible foods, WeWork and Anglo American April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 16:15 GMT on Monday: ** Impossible Foods, which makes meat alternatives from soy, is targeting a "liquidity event" that could include a public offering in the next two to three years, CEO Peter McGuinness told Reuters.
A
M
N
T
A

Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked

BRIEF-Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked April 29 (Reuters) - MorphoSys AG MORG.DE : MORPHOSYS' 2024 FINANCIAL GUIDANCE PUBLISHED ON JANUARY 30, 2024, CANNOT BE MAINTAINED AND THEREFORE WAS REVOKED WILL NO LONGER MAKE A FORECAST FOR GROSS MARGIN OR REVENUES FROM MONJUVI PRODUCT SALES COST OF SALES IN Q1 OF 2024 AMOUNTED TO EUR 2.8 MILLION (3M 2023: EUR 1.0 MILLION) FOR 2024, MORPHOSYS EXPECTS RESEARCH AND DEVELO
M

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Manipal Hospitals, WEC Energy Group, Thyssenkrupp, UMB Financial Corp, Investcorp, Deciphera; updates BHP Group, Morphosys April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** India's Manipal Hospitals said it will acquire an 87% stake in Medica Synergie as it aims to expand its footprint in eastern India.
A
M
N
T
A

Morphosys says takeover by Novartis on course after report of drug safety concern

UPDATE 1-Morphosys says takeover by Novartis on course after report of drug safety concern Writes through with detail, background, no Novartis comment; adds shares in final paragraph BERLIN, April 29 (Reuters) - Morphosys MORG.DE said its takeover by Novartis NOVN.S is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday.
M
N

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** Morphosys MORG.DE said its takeover by Novartis NOVN.S was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price.
A
M
N
A

Morphosys says Novartis takeover progressing as planned for H1 2024

Morphosys says Novartis takeover progressing as planned for H1 2024 BERLIN, April 29 (Reuters) - Morphosys MORG.DE said its takeover by Novartis NOVN.S was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price on Monday.
M
N

MorphoSys AG <MOR.OQ> expected to post a loss of 32 cents a share - Earnings Preview

MorphoSys AG expected to post a loss of 32 cents a share - Earnings Preview MorphoSys AG MOR.OQ , MOR.O is expected to show a fall in quarterly revenue when it reports results on April 29 for the period ending March 31 2024 The Planegg Bayern-based company is expected to report a 11.0% decrease in revenue to €55.448 million from €62.32 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
M

Morphosys To Present New Phase 3 Manifest-2 Data On Pelabresib In Myelofibrosis

BRIEF-Morphosys To Present New Phase 3 Manifest-2 Data On Pelabresib In Myelofibrosis April 24 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS TO PRESENT NEW PHASE 3 MANIFEST-2 DATA ON PELABRESIB IN MYELOFIBROSIS IN ORAL PRESENTATION AT 2024 ASCO ANNUAL MEETING Source text for Eikon: ID:nEQ81FfT1a Further company coverage: MORG.DE (Gdansk Newsroom)
M

Novartis raises guidance after beating Q1 expectations

UPDATE 4-Novartis raises guidance after beating Q1 expectations Adds analyst comment, shares in paragraphs 6-7 By Ludwig Burger FRANKFURT, April 23 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its full-year guidance on wider use of psoriasis and arthritis drug Cosentyx on Tuesday and said it had tapped the former boss of Bristol Myers Squibb (BMS) to become its chairman next year.
M
N



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔